Incyte Biosciences Japan GK
Clinical trials sponsored by Incyte Biosciences Japan GK, explained in plain language.
Japanese subsidiary of Incyte, a biopharmaceutical company focused on oncology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug combo shows promise against blood cancer in japanese trial
Disease control OngoingThis study tests the safety and effectiveness of tafasitamab, given alone or with other drugs (lenalidomide, parsaclisib, or R-CHOP), in about 72 Japanese adults with Non-Hodgkin lymphoma. The goal is to find the best doses and see if the treatment shrinks tumors. Participants ha…
Phase 1/2 • Sponsor: Incyte Biosciences Japan GK • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for japanese patients with Hard-to-Treat chronic GVHD
Disease control OngoingThis study tests a drug called axatilimab in Japanese patients with chronic graft-versus-host disease (cGVHD) that has not improved after at least two prior treatments. cGVHD is a complication of stem cell transplants where donor cells attack the patient's body. The goal is to se…
Phase 3 • Sponsor: Incyte Biosciences Japan GK • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC